Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP)
Post# of 721
(Total Views: 255)
Posted On: 03/16/2018 5:00:48 PM
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Aims to Generate up to 80% of Revenues from Technology Licensing
- CEO Chris Bunka says in audio interview that human study of company’s proprietary TurboCBD technology will start in April outside of North America
- Hopes to add 6-12 more IP technology licensing contracts within year
- Cutting-edge research designed to attract the attention of tobacco and cannabis industries
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) CEO Chris Bunka said in a recent audio interview that, although consumer products will always be important to LXRP, he estimates that up to 80 percent of its revenues could be generated through the licensing of its proprietary technology to other companies (http://nnw.fm/6sEoP).
LXRP is a British Columbia, Canada-based bioscience company that is a drug delivery platform innovator. The company has developed its patented DehydraTECH™ delivery technology platform, which it out-licenses to promote healthier ingestion methods and lower overall dosing.
Bunka said that LXRP believes that 6-12 more licensing contracts will be signed this year, both generating more revenue for the company and building greater shareholder value. “We’ve only just graduated from the demonstration phase,” he explained in the interview.
“The latest contracts are typically six figure contracts in the first year and potentially seven figure contracts over the life of the contracts,” Bunka added. “They’re becoming bigger.” The company sees a potential game changer for itself in three new sets of studies and believes that each could be material to the valuation of the company.
The first is a completed study of the company’s proprietary DehydraTECH in the form of a topical cream for the absorption of cannabidiol (CBD) through human skin (http://nnw.fm/3N45v). LXRP said that results showed significant increases in quantity and speed of CBD absorption through the skin when compared to other formulations.
The second is a lab animal study that tests nicotine absorption. Using lab rats, the study measures gastrointestinal distress (http://nnw.fm/WYgh8). It will take blood and tissue samples at pre-prescribed time intervals to measure nicotine absorption. It will test LXRP’s ‘Trojan horse’ technology that may hide it from a negative response triggered by the body, Bunka said. An end goal is to bypass liver absorption and help avoid kidney and liver diseases associated with some of these substances by using LXRP technologies.
The third is a clinical human study first started with a Canadian University. Now, it has been moved out of North America into another institution, and the study’s initiation is imminent, he added. The study is on the cardiovascular and health effects of the company’s TurboCBD™ (http://nnw.fm/aHF4p). Bunka at the time said that the study would permit LXRP to custom design products that would increase the performance its technology already offers to customers.
“That study is now back on track. We expect it to begin in the month of April in a different location,” Bunka noted.
He added that all three studies, or any one of them, could mean a major change for the company, as its IP and studies attract increased interest from both the tobacco and cannabis industries. Lexaria has developed cutting-edge technologies with commercial application, he said in the interview.
“Those three studies, each one of those, has the potential to be a real game changer in the valuation of the company,” Bunka said.
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- CEO Chris Bunka says in audio interview that human study of company’s proprietary TurboCBD technology will start in April outside of North America
- Hopes to add 6-12 more IP technology licensing contracts within year
- Cutting-edge research designed to attract the attention of tobacco and cannabis industries
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) CEO Chris Bunka said in a recent audio interview that, although consumer products will always be important to LXRP, he estimates that up to 80 percent of its revenues could be generated through the licensing of its proprietary technology to other companies (http://nnw.fm/6sEoP).
LXRP is a British Columbia, Canada-based bioscience company that is a drug delivery platform innovator. The company has developed its patented DehydraTECH™ delivery technology platform, which it out-licenses to promote healthier ingestion methods and lower overall dosing.
Bunka said that LXRP believes that 6-12 more licensing contracts will be signed this year, both generating more revenue for the company and building greater shareholder value. “We’ve only just graduated from the demonstration phase,” he explained in the interview.
“The latest contracts are typically six figure contracts in the first year and potentially seven figure contracts over the life of the contracts,” Bunka added. “They’re becoming bigger.” The company sees a potential game changer for itself in three new sets of studies and believes that each could be material to the valuation of the company.
The first is a completed study of the company’s proprietary DehydraTECH in the form of a topical cream for the absorption of cannabidiol (CBD) through human skin (http://nnw.fm/3N45v). LXRP said that results showed significant increases in quantity and speed of CBD absorption through the skin when compared to other formulations.
The second is a lab animal study that tests nicotine absorption. Using lab rats, the study measures gastrointestinal distress (http://nnw.fm/WYgh8). It will take blood and tissue samples at pre-prescribed time intervals to measure nicotine absorption. It will test LXRP’s ‘Trojan horse’ technology that may hide it from a negative response triggered by the body, Bunka said. An end goal is to bypass liver absorption and help avoid kidney and liver diseases associated with some of these substances by using LXRP technologies.
The third is a clinical human study first started with a Canadian University. Now, it has been moved out of North America into another institution, and the study’s initiation is imminent, he added. The study is on the cardiovascular and health effects of the company’s TurboCBD™ (http://nnw.fm/aHF4p). Bunka at the time said that the study would permit LXRP to custom design products that would increase the performance its technology already offers to customers.
“That study is now back on track. We expect it to begin in the month of April in a different location,” Bunka noted.
He added that all three studies, or any one of them, could mean a major change for the company, as its IP and studies attract increased interest from both the tobacco and cannabis industries. Lexaria has developed cutting-edge technologies with commercial application, he said in the interview.
“Those three studies, each one of those, has the potential to be a real game changer in the valuation of the company,” Bunka said.
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LXRPD) Stock Research Links
Scroll down for more posts ▼